Haleon plc:
Completion of
off-market purchase and Total Voting Rights and
Capital
3
October 2024: Haleon plc (the
"Company" or "Haleon") (LSE/NYSE: HLN) today announces that it has completed the
off-market purchase of 60,526,315 ordinary shares of £0.01 each,
repurchased from Pfizer Inc. ("Pfizer") for an aggregate purchase
price of £230 million.
The off-market purchase includes (i)
30,161,278 ordinary shares which Haleon has cancelled and (ii)
30,365,037 ordinary shares which will be held as treasury
shares.
As at 3 October 2024, the total
number of ordinary shares issued by Haleon is 9,083,725,919, of which
30,365,037 are held as treasury shares. Therefore, the number of
ordinary shares with voting rights is 9,053,360,882 and this figure
may be used by shareholders (and others with notification
obligations) as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
|
Sonya
Ghobrial
|
+44 7392 784784
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh
Patel
|
+44 7552 484646
|
Gemma Thomas
|
+44 7985 175048
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email:
investor-relations@haleon.com
|
Email:
corporate.media@haleon.com
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in
consumer health, with a purpose to deliver better everyday health
with humanity. Haleon's product portfolio spans five major
categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements
(VMS). Its long-standing brands - such as Advil, Sensodyne,
Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and
Centrum - are built on trusted science, innovation and deep human
understanding.
For more information please visit
www.haleon.com
